<DOC>
	<DOCNO>NCT00003274</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . It yet know preparation vaccine therapy effective treating melanoma . PURPOSE : Randomized phase II trial study effectiveness tyrosinase/gp100 peptide vaccine treat patient stage II melanoma remove surgery .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage II Melanoma That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine immune reactivity HLA-A2 positive patient resectable stage IIA IIB melanoma treat vaccine comprise tyrosinase peptide gp100 antigen emulsify Montanide ISA-51 ( ISA-51 ) alone combination sargramostim ( GM-CSF ) . OUTLINE : This randomize , multicenter study . Patients stratify accord stage ( IIA v IIB ) . Patients randomize 1 2 treatment arm : Arm I : Patients receive vaccine comprise tyrosinase peptide gp100 antigen emulsify Montanide ISA-51 ( ISA-51 ) alone subcutaneously ( SQ ) week week 0 , 2 , 4 , 6 , 10 , 14 , 18 , 26 . Arm II : Patients receive treatment arm I follow sargramostim ( GM-CSF ) SQ 5 day vaccination . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 50 patient ( 25 per arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIA stage IIB resectable cutaneous melanoma render disease free Clinically uninvolved lymph node physical examination OR Pathologically uninvolved lymph node sentinel lymph node either complete node dissection selective lymphadenectomy , respectively No evidence metastatic disease within 28 day prior definitive surgery HLAA2 positive PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Hematopoietic : No coagulation disorder No significant hematologic abnormality Hepatic : Bilirubin great 2.0 mg/dL No significant liver abnormality Renal : Creatinine great 2.0 mg/dL No significant kidney abnormality Cardiovascular : No major medical illness cardiovascular system Pulmonary : No major medical illness respiratory system Other : No know allergic reaction Montanide ISA51 sargramostim ( GMCSF ) No major systemic infection Not pregnant nursing HIV negative Hepatitis B surface antigen negative Hepatitis C antibody negative No prior uveitis autoimmune inflammatory eye disease No active autoimmune disease No malignancy within past 5 year PRIOR CONCURRENT THERAPY : At least 1 month since prior adjuvant therapy therapy cancer Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent steroid therapy Radiotherapy : At least 1 month since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage II melanoma</keyword>
</DOC>